Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H. F., … Venook, A. P. (2015). Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). In Journal of Clinical Oncology (Vol. 33, pp. 4005–4005). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.4005

Kulke, Matthew H., Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen F. Kennecke, Edward M. Wolin, and Alan P. Venook. “Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).” In Journal of Clinical Oncology, 33:4005–4005. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4005.

Kulke MH, Niedzwiecki D, Foster NR, Fruth B, Kunz PL, Kennecke HF, et al. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 4005–4005.

Kulke, Matthew H., et al. “Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 4005–4005. Crossref, doi:10.1200/jco.2015.33.15_suppl.4005.

Kulke MH, Niedzwiecki D, Foster NR, Fruth B, Kunz PL, Kennecke HF, Wolin EM, Venook AP. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 4005–4005.